The transmembrane segment IIIS5 of the L-type calcium channel ␣ 1 subunit participates in the formation of the 1,4-dihydropyridine (DHP) interaction domain (Grabner, M., Wang, Z., Hering, S., Striessnig, J., and Glossmann, H. (1996) Neuron 16, 207-218). We applied mutational analysis to identify amino acid residues within this segment that contribute to DHP sensitivity. DHP agonist and antagonist modulation of Ba 2؉ inward currents was assessed after coexpression of chimeric and mutant calcium channel ␣ 1 subunits with ␣ 2 ␦ and ␤ 1a subunits in Xenopus oocytes. Whereas DHP antagonists required Thr-1066, DHP agonist modulation crucially depended on the additional presence of Gln-1070 (numbering according to ␣ 1C-a ), which also further increased the sensitivity to DHP antagonists. Asp-955, which is found at the corresponding position in the calcium channel ␣ 1S subunit from carp skeletal muscle, displayed functional similarity to Gln-1070 with respect to DHP interaction. We conclude that these residues (Thr-1066 plus Gln-1070 or Asp-955), which are located in close vicinity on the same side of the putative ␣-helix of transmembrane segment IIIS5, form a crucial DHP binding motif.
The transmembrane segment IIIS5 of the L-type calcium channel ␣ 1 subunit participates in the formation of the 1,4-dihydropyridine (DHP) interaction domain (Grabner, M., Wang, Z., Hering, S., Striessnig, J., and Glossmann, H. (1996) Neuron 16, 207-218). We applied mutational analysis to identify amino acid residues within this segment that contribute to DHP sensitivity. DHP agonist and antagonist modulation of Ba 2؉ inward currents was assessed after coexpression of chimeric and mutant calcium channel ␣ 1 subunits with ␣ 2 ␦ and ␤ 1a subunits in Xenopus oocytes. Whereas DHP antagonists required Thr-1066, DHP agonist modulation crucially depended on the additional presence of Gln-1070 (numbering according to ␣ 1C-a ), which also further increased the sensitivity to DHP antagonists. Asp-955, which is found at the corresponding position in the calcium channel ␣ 1S subunit from carp skeletal muscle, displayed functional similarity to Gln-1070 with respect to DHP interaction. We conclude that these residues (Thr-1066 plus Gln-1070 or Asp-955), which are located in close vicinity on the same side of the putative ␣-helix of transmembrane segment IIIS5, form a crucial DHP binding motif.
Voltage-dependent calcium channels rapidly and selectively mediate calcium entry into excitable cells. According to their electrophysiological and pharmacological properties, N-, L-, T-, P-, Q-, and R-type channels are distinguished (for review, see Refs. [1] [2] [3] [4] . L-type channel function is modulated by 1,4-dihydropyridine (DHP) 1 calcium agonists and antagonists. The latter are used in the treatment of cardiovascular disorders, such as hypertension and ischemic heart disease (5) .
To fully understand the molecular mechanism of channel modulation by these drugs, the identification of amino acid residues that are involved in DHP binding to L-type calcium channels is required. Photoaffinity labeling combined with antibody mapping (6) , as well as mutational analysis (7) (8) (9) (10) , identified segments IIIS6 and IVS6 and the S5-S6 linkers in repeats III and IV of the ␣ 1 subunits to form the DHP interaction domain. We recently demonstrated that introducing only as much as 9.4% L-type sequence into the DHP-insensitive class A (BI-2) calcium channel ␣ 1 subunit is sufficient to transfer drug sensitivity (8) . A significant new finding of this study was that segment IIIS5 is critically involved in formation of the DHP interaction domain.
Here we employed site-directed mutagenesis and heterologous expression in Xenopus oocytes to examine the impact of individual amino acid residues within segment IIIS5 on DHP action. We found that Thr-1066 and Gln-1070 of ␣ 1C-a differentially contribute to DHP agonist and antagonist effects. These residues are located in close vicinity on the same side in a putative ␣-helix of transmembrane segment IIIS5. Since the additional sequence stretches of the DHP binding pocket are formed by putatively pore-lining segments (11), our data suggest that segment IIIS5 must also be located close to or within the pore of L-type calcium channels.
EXPERIMENTAL PROCEDURES
Chimeric ␣ 1 cDNAs-Construction of class A/L-type chimeric ␣ 1 subunits AL1, AL12h, and AL12s, derived from the DHP-insensitive rabbit brain class A calcium channel (BI-2) ␣ 1A (A; Ref. 12) and from the DHP-sensitive L-type channels from rabbit heart ␣ 1C-a (C; Ref. 13 ) and carp skeletal muscle ␣ 1S (S; Ref. 14) , as well as their insertion into the polyadenylating transcription plasmid pNKS2 (provided by O. Pongs, ZFMNB, Hamburg, Germany) was described previously (8) . Chimeras and mutants thereof were constructed as follows ("silent" restriction sites generated by polymerase chain reaction in previous cloning steps (8) are indicated by asterisks): AL16 (amino acid numbering given in parentheses), A(1-1408), C(1082-1197), A(1522-1723), C(1413-1506), A(1821-2424); an intermediate subclone (nucleotide numbers in parentheses) XhoI (A, 1679)-ClaI* (A, 4925) fragment of AL12h in pBluescript SKϩ (Stratagene) was generated for the insertion of the SfiI (A, 4287)-BglII (C, 3704) cut cDNA-fragment created by gene splicing by overlap extension (15) (transition: A, 4511/C, 3437). The XhoI-ClaI* fragment (A, 1679 -A, 4925) of the subclone was subsequently isolated and ligated into XhoI-ClaI* cut AL12h. Gene splicing by overlap extension and XhoI-ClaI* cassette cloning was also applied to introduce point mutations into AL1 and AL16 by using mutagenic polymerase chain reaction primers. AL16, as the parent chimera, yielded mutants AL17, AL17/-T, AL17/-L, AL17/-Q, AL17/-M, AL17/-G, AL16/ϩT, AL16/ϩTQ, and AL17/QD, whereas AL1 yielded mutants AL1/ϩTD, AL1/ϩTQ, and AL1/ϩLDM. Polymerase chain reaction was performed as described previously (8) using proofreading Pfu polymerase (Stratagene). The integrity of all polymerase chain reaction-generated fragments was confirmed by sequence analysis using the dideoxy chain termination method (16) .
Expression of ␣ 1 Chimeras in X. laevis Oocytes-Preparation of stage V-VI oocytes from X. laevis and injection of cRNA are described in detail elsewhere (8) . Capped run-off poly(Aϩ) cRNA transcripts from XbaI-linearized cDNA templates were synthesized according to the procedures of Krieg and Melton (17) . ␣ 1 cRNAs (15 pg-1.5 ng/50 nl) were coinjected with approximately equimolar ratios of ␤ 1a (18) and ␣ 2 ␦ (19) subunit cRNAs.
Voltage Clamp Measurements-Ba 2ϩ inward currents (I Ba ) through voltage-gated calcium channels were measured between 2 and 5 days after injection of cRNA using the two-microelectrode voltage-clamp technique (Turbo Tec 01C, NPI-Electronic, Tamm, Germany). Voltagerecording microelectrodes and current-injecting electrodes were filled with 2.8 M CsCl, 0.2 M CsOH, 10 mM EGTA, 10 mM HEPES (pH 7.4) and had resistances of 0.3-1 M⍀. All experiments were carried out at room temperature using Ba 2ϩ as the charge carrier in a solution composed of 40 mM Ba(OH) 2 , 40 mM N-methyl-D-glucamine, 10 mM HEPES, and 10 mM glucose (pH adjusted to 7.4 with methanesulfonic acid). The recording chamber (volume, 150 l) was continuously perfused with a flow rate of 1 ml/min. Drug-containing solutions were applied with identical flow rate. Leakage current correction was performed digitally, by using average values of scaled leakage currents elicited by hyperpolarizing voltage pulses (P/4 protocol). The pClamp software package (version 5.51, Axon Instruments, Inc.) was used for data acquisition and analysis. Data were filtered at 1 kHz, digitized at 0.2 kHz, and stored on a computer hard disk.
Benzoxadiazol DHPs were from Sandoz AG, BayK 8644 was from Bayer AG, and FPL 64176 was from Fisons Pharmaceuticals.
Statistics-Data are given as means Ϯ S.E. from the indicated number of experiments. Statistical significance was calculated using the unpaired t test.
RESULTS AND DISCUSSION

Two Amino Acid Residues of L-type IIIS5 Segments Form
Part of the DHP Interaction Domain-Transmembrane segment IIIS5 is crucial for the transfer of the DHP sensitivity from class C (or S) to class A (BI) calcium channels (8) . To identify amino acid residues responsible for DHP interaction within this segment, we used a "constructive" approach by determining which L-type amino acid residues must be introduced into class A IIIS5 sequence to generate DHP sensitivity ( Fig. 1 ). For this purpose the DHP-insensitive chimera AL16 was created as a starting point. AL16 was constructed by replacing the IIIS5 segment of the DHP-sensitive "minimum" chimera AL12h (8) , derived from ␣ 1C-a (13) , with the corresponding sequence of ␣ 1A (12) (Fig. 1A ; for a detailed description see "Experimental Procedures"). As expected from the findings obtained with the analogous chimera AL1 (8) , where the remaining L-type sequence stretches were derived from carp ␣ 1S (14) , AL16 was completely insensitive to 10 M solutions of the DHP antagonist (Ϯ)-isradipine or the DHP agonist (Ϯ)-BayK 8644 (Fig. 1B) .
The 9-amino acid difference between AL16 and AL12h must account for their different DHP sensitivity. Four of these amino acids represent highly conserved residues within all cloned L-type and non-L-type calcium channel ␣ 1 subunits, respec- tively. We therefore considered the L-type amino acids Thr, Leu, Met, and Gly of this set to be prime candidates for the interaction with DHPs. Consequently, we generated a quadruple mutant from AL16 (as the parent chimera) by replacing Tyr-1393, Phe-1396, Ile-1399, and Ala-1404 (numbering according to ␣ 1A ) with the corresponding L-type amino acids Thr-1066, Leu-1069, Met-1072, and Gly-1077 (numbering according to ␣ 1C-a ). The resulting construct, termed AL17/-Q, indeed displayed sensitivity toward (Ϯ)-isradipine (Fig. 1B) , although inhibition of I Ba by 10 M of this DHP antagonist was significantly (p Ͻ 0.05) reduced, compared with AL12h. Interestingly, AL17/-Q was entirely insensitive to the DHP agonist (Ϯ)-BayK 8644 (Fig. 1B) . From this finding it was obvious that other or additional mutations to the L-type sequence were required to introduce DHP agonist sensitivity.
A further candidate for substitution by the L-type sequence was Met-1397. At the corresponding position, L-type ␣ 1 subunits possess a glutamine residue (Gln-1070 of ␣ 1C-a ). The only exception is the ␣ 1S from carp skeletal muscle that carries an aspartate residue instead (14) . Replacing Met-1397 of ␣ 1A with Gln-1070 of ␣ 1C-a yielded AL17, which indeed displayed full sensitivity to (Ϯ)-BayK 8644 as well as (Ϯ)-isradipine, indistinguishable from AL12h (Fig. 1B) .
On the basis of this finding, we investigated the contribution of Thr-1066, Leu-1069, Met-1072, and Gly-1077 to DHP sensitivity by introducing single amino acid exchanges from L-type to non-L-type sequence into AL17. The resulting mutants were designated AL17/-T, AL17/-L, AL17/-M, and AL17/-G, respectively. As shown in Fig. 1B , three of these mutants (AL17/-L, AL17/-M, and AL17/-G) remained sensitive to the agonist as well as the antagonist, whereas mutation T1066Y in AL17/-T rendered this construct completely insensitive to DHP agonist and antagonist action. These results suggest that two amino acids in the IIIS5 segment of L-type calcium channels are crucial for DHP sensitivity and display a differential effect. Whereas Thr-1066 mediates substantial DHP antagonist sensitivity, a combination of Thr-1066 and Gln-1070 is necessary for the interaction with the DHP agonist (Ϯ)-BayK 8644.
This was directly confirmed by introducing Thr-1066 alone, as well as Thr-1066 plus Gln-1070, into the class A IIIS5 segment of AL16. This yielded AL16/ϩT (Y1393T) and AL16/ ϩTQ (Y1393T plus M1397Q) (Fig. 1B) . As shown in Fig. 1B , AL16/ϩTQ exhibited full sensitivity to DHP antagonist and agonist action. Block of peak current by 10 M (Ϯ)-isradipine, as well as current increase by 10 M (Ϯ)-BayK 8644, was indistinguishable from the values obtained from minimum chimera AL12h. Like its counterpart AL17/-Q, AL16/ϩT was insensitive to (Ϯ)-BayK 8644, confirming the crucial role of this residue for DHP agonist action. Antagonist sensitivity of AL16/ϩT is also closely correlated with AL17/-Q in a significant (p Ͻ 0.01) reduction of block by 10 M (Ϯ)-isradipine compared to AL12h, suggesting a decrease of DHP antagonist affinity when only threonine is present in IIIS5.
Properties of AL16/ϩT and AL16/ϩTQ- Fig. 2 illustrates the electrophysiological properties and DHP sensitivity of AL16, AL16/ϩTQ, and AL16/ϩT. The threshold potential of all three constructs was between Ϫ50 and Ϫ40 mV. Maximal current amplitudes were reached at test potentials ranging from Ϫ20 to Ϫ10 mV. Inward currents through AL16 were unaffected by 10 M solutions of (Ϯ)-BayK 8644 and (Ϯ)-isradipine at all test potentials (Fig. 2A) . The I Ba of AL16/ϩTQ was stimulated by the DHP agonist (Ϯ)-BayK 8644 (10 M) 3.1-3.9-fold at test potentials of Ϫ20 mV, and 69 Ϯ 6% of the peak-I Ba was blocked by the DHP antagonist (Ϯ)-isradipine (10 M) at a test potential of 0 mV (Fig. 2B) . As shown in Fig. 2B , AL16/ ϩTQ displayed all features of BayK 8644 modulation of native L-type currents (20, 21) . BayK 8644 increased Ba 2ϩ inward current, slowed current activation, shifted the peak as well as the midpoint voltage of the current activation curve to more negative potentials, and slowed channel deactivation. AL16/ϩT was unique with respect to its modulation by DHPs. Whereas 10 M (Ϯ)-isradipine blocked the barium inward current, the agonist (Ϯ)-BayK 8644 (10 M) was clearly ineffective in stimulating I Ba (Fig. 2C) . However, the extent of inhibition by 10 M (Ϯ)-isradipine was reduced compared to chimera AL12h (Fig.  1B) , suggesting a decrease in DHP antagonist affinity.
The concentration dependence of (Ϯ)-isradipine block was therefore assessed for AL16/ϩTQ and AL16/ϩT (Fig. 3A) . Whereas the apparent potency for block of I Ba through AL16/ ϩTQ was comparable to chimeras AL12s (8) and Lh (8), we observed a 35-fold increase in the IC 50 value of (Ϯ)-isradipine for AL16/ϩT (Fig. 3A) . Nevertheless, AL16/ϩTQ, as well as AL16/ϩT, was clearly stereoselective for the enantiomers of isradipine (Fig. 3, B and C) .
Sensitivity to Other Calcium Channel Modulators-The difference between agonist and antagonist effects on AL16/ϩT and AL16/ϩTQ could be due to the different chemical structure of these compounds, since isradipine but not BayK 8644 is a benzoxadiazol-DHP. To rule out this possibility and to exclude the possibility that the differential contribution of L-type Thr-1066 and Gln-1070 on agonist and antagonist action is restricted to these two probes, the stereoisomers of the benzoxadiazol-DHP 202-791 were tested (Fig. 4) . The effects elicited by (ϩ)-202-791 (agonist) and (Ϫ)-202-791 (antagonist) were indistinguishable from (Ϯ)-BayK 8644 and (Ϯ)-isradipine, respectively (Fig. 4) . Like BayK 8644, (ϩ)-202-791 required Gln-1070 of AL16/ϩTQ to display the typical agonist effect (Fig.  4A) .
This also holds true for the benzoyl pyrrole L-type calcium channel agonist FPL 64176, which is structurally unrelated to DHPs. 10 M FPL 64176 activated the current through AL16/ ϩTQ (Fig. 4A) but not AL16/ϩT (Fig. 4B) . Since radioligand binding studies have found a noncompetitive interaction between FPL 64176 and DHPs (22, 23) , these drugs may interact with different residues in other regions of the DHP binding pocket. However, Gln-1070 seems to function as a common molecular determinant for the action of these channel activators.
The evidence that a threonine and glutamine residue in IIIS5 together contribute to the formation of a fully functional DHP binding pocket can be summarized as follows: first, together these residues conferred DHP agonist and antagonist action indistinguishable from DHP-sensitive wild-type ␣ 1 subunits or AL12h (8) . Displaying a differential effect, threonine represents an absolute requirement for DHP action. Glutamine supported no DHP sensitivity in the absence of threonine (chimera AL17/-T), but is required for an agonist effect and an increase in antagonist sensitivity. The agonistic effect of DHPs was not only found for BayK 8644 but also for the benzoxadiazol derivative (ϩ)-202-791 and the structurally unrelated benzoyl pyrrole FPL 64176. Second, inhibition by DHP antagonists was clearly stereoselective, (ϩ)-isradipine being the more potent enantiomer. Third, the modulation of I Ba through AL16/ ϩTQ showed the typical characteristics of L-type channel modulation by DHP agonists as found for AL12h (8) and native L-type calcium channels (20, 21) .
An Aspartate Residue Is Functionally Similar to Glutamine-Because the highly conserved glutamine residue in L- FIG. 3 . Pharmacological properties of AL16/؉TQ and AL16/؉T. A, concentration-response curves of (Ϯ)-isradipine for inhibition of peak-I Ba carried by AL16/ ϩTQ (circles) and AL16/ϩT (squares). Data from three recordings are given as mean Ϯ S.E. IC 50 values (Ϯ S.D.; AL16/ ϩTQ, 133 Ϯ 57 nM; AL16/ϩT, 4.7 Ϯ 1.3 M) were calculated by fitting the experimental data to the general dose response equation (28) . B and C, stereoselective inhibition of I Ba through AL16/ϩTQ (B) and AL16/ϩT (C) by 1 M solutions of (ϩ)-and (Ϫ)-isradipine. Currents were recorded after depolarization to a test potential of 0 mV from a holding potential of Ϫ80 mV. Representative current traces of at least three experiments are shown. type IIIS5 segments is replaced by an aspartate in the DHPsensitive carp ␣ 1S , we investigated whether glutamine can be substituted by aspartate in our chimeric constructs. We started by replacing Tyr-1393 and Met-1397 (numbering according to ␣ 1A ) of the carp skeletal muscle ␣ 1S -derived chimera AL1 with Thr-951 and Asp-955 (numbering according to carp ␣ 1S ), respectively. As shown in Fig. 1C , the resulting double mutant AL1/ϩTD exhibited sensitivity to 10 M solutions of the antagonist (Ϯ)-isradipine as well as the agonist (Ϯ)-BayK 8644. The functional importance of Thr-951 was confirmed by the absence of agonist as well as antagonist sensitivity in mutant AL1/ ϩLDM (compare AL17/-T in Fig. 1B) . These findings demonstrate that in the IIIS5 segment of the DHP-insensitive chimera AL1, replacement of tyrosine and methionine by threonine and aspartate, respectively, is sufficient to generate DHP sensitivity in carp ␣ 1S -derived L-type environment.
Because different L-type sequences were used to construct the DHP interaction domain in chimeras AL16/ϩTQ and AL1/ ϩTD (␣ 1C-a versus carp ␣ 1S , respectively), we were interested in whether interchanging Asp and Gln in these different L-type environments is tolerated with respect to agonist modulation. We therefore constructed two additional mutants by replacing Gln-1070 of AL17 (␣ 1C-a origin) with aspartate (yielding AL17/ QD; Fig. 1B ) and Asp-955 of AL1/ϩTD (␣ 1S origin) with glutamine (yielding AL1/ϩTQ; Fig. 1C ). Both mutants displayed sensitivity toward 10 M solutions of (Ϯ)-isradipine and (Ϯ)-BayK 8644, although the extent of BayK 8644 modulation varied with respect to amplification of Ba 2ϩ inward current (Fig. 1, B and C) . Nevertheless, BayK 8644 slowed current activation; shifted the peak amplitude, as well as the midpoint voltage, of the current activation curve to more negative potentials; and slowed channel deactivation in all cases (not shown). This finding indicated that aspartate supports DHP modulation, regardless of whether L-type sequence in the remaining binding pocket was from ␣ 1S (in AL1/TD and AL1/TQ) or ␣ 1C-a (in AL16/TQ and AL17/QD). The extent of antagonist modulation was equivalent for all of these mutants. In contrast, current stimulation by BayK 8644 was less pronounced for the mutants containing aspartate instead of glutamine. This confirmed our finding that agonist sensitivity more critically depended on the additional presence of glutamine (or aspartate in the corresponding position) than did antagonist sensitivity. In addition, the extent of agonist modulation mediated by glutamine and aspartate seemed to be slightly influenced by the overall structure of the DHP binding domain generated by the remaining L-type sequence environment (compare AL17/QD and AL1/TQ). Even though the difference in the extent of current stimulation displayed by AL1/TD and AL12s was statistically insignificant (p Ͻ 0.01), we cannot rule out that one or more additional L-type residues are required to compensate for the difference between glutamine and the aspartate in carp ␣ 1S .
Because the side chain lengths of glutamine and methionine, which does not mediate DHP sensitivity, are very similar, the effect of the glutamine (and aspartate) residue is unlikely to be through steric fit. Instead, interaction with DHPs could be mediated through the carbonyl group, present both in glutamine and aspartate, serving as a hydrogen bond acceptor. This interaction could be slightly impaired by the charged moiety of aspartate. A detailed structure-activity analysis of the effect of different amino acids in this position may allow further insight into the mechanism of DHP interaction with IIIS5.
Implications for Channel Structure-Similar to the molecular determinants for the block of voltage-dependent sodium channels by local anesthetics (24), as well as for the block of voltage-dependent calcium channels by phenylalkylamines (25, 26), the residues within IIIS5 responsible for functional interaction with DHP compounds are positioned in close vicinity to each other (i.e. within about 0.5 nm) on the same side of a putative ␣-helix (Fig. 5) . As additional structural determinants of the DHP binding pocket outside IIIS5 are contained within transmembrane segments IIIS6 and IVS6 and the S5-S6 linkers of repeats III and IV (6 -10), which represent pore-forming regions (11) of the ␣ 1 subunit, the two IIIS5 residues are also most likely located within or close to the ion-conducting pathway. Our data are therefore consistent with current folding models of voltage-gated cation channels, which also place S5 segments near (11) or at the channel pore (27) .
The functional similarity of the structurally different amino acids glutamine and aspartate could provide valuable information for the identification of a common structural motif underlying the modulation of calcium channels by DHPs. Structural information on ligand-channel interaction will eventually converge with information on the molecular determinants of calcium channel gating and thereby generate a refined picture of calcium channel function.
